Investigators from the Spanish Lung Cancer Group conducted the largest-ever study to examine the benefits of customizing lung cancer treatment based on mutations in the epidermal growth factor receptor (EGFR) gene.
At the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm they report that patients with the mutations survived for almost two years on average when treated with erlotinib.
“For the first time in lung cancer management, doctors are able, by testing EGFR mutations, to identify a subgroup of patients (between 15-22% according to our experience) who can obtain a new survival landmark in advanced non-small-cell lung cancer, with oral EGFR inhibitors like erlotinib,” said Prof. Rafael Rosell, who presented the new data at the meeting.
The Spanish group took tumor biopsies from 2,312 patients with advanced non-small-cell lung cancer and screened them for two common mutations in the gene for epidermal growth factor receptor, which can be a cause of lung cancer.
The two mutations they screened for were a deletion in exon 19 of the receptor’s tyrosine kinase domain, and a mutation in exon 21. Tumors with EGFR mutations are more frequently seen in people who have never smoked and in women.
The group identified 307 patients who carried the EGFR mutations. Each was treated with erlotinib.
Based on data from 193 patients, the mean survival was 22 months, Prof. Rosell reported. For women, the mean survival was 28 months; for men, 17 months. Mean time to progression was 12 months overall, and was longer in women than in men.
The researchers saw a response to treatment in 71% of patients, including 24 patients who experienced a complete response. The probability of response was twice as high in patients aged 61-71 years and in patients with the exon 19 deletion.
“Therefore non-small-cell lung cancers with EGFR mutations display a two-to-three-fold increment in outcome in comparison with non-small-cell lung cancers treated with chemotherapy, in which median survival is 11 months, time-to-progression is 5 months, and response 20-30%,” Prof. Rosell said.
“These results are a new clinical discovery. The impressive survival and response are undeniable. This is a new landmark of treatment in non-small-cell lung cancer, and the first tangible target for customizing treatment with EGFR tyrosine kinase inhibitors.”
Vanessa Pavinato | alfa
Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign
Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences